<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04470934</url>
  </required_header>
  <id_info>
    <org_study_id>AAG-O-H-1913</org_study_id>
    <nct_id>NCT04470934</nct_id>
  </id_info>
  <brief_title>SeQuent® SCB &quot;All Comers&quot; Post Market Clinical Follow-up (PMCF)</brief_title>
  <acronym>SCORE</acronym>
  <official_title>PMCF - Study on the Performance/Safety of SeQuent® Sirolimus-Coated Balloon (SCB, Investigational Device) in Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Melsungen AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess continued safety and efficacy of the SeQuent® SCB. The&#xD;
      product under investigation will be used in routine clinical practice according to the latest&#xD;
      European Society of Cardiology (ESC) guidelines and according to the Instructions for Use&#xD;
      (IFU). Those data that are obtained in routine clinical use will be documented in the Case&#xD;
      Report Form (CRF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to assess the continued safety and efficacy of SeQuent® SCB for&#xD;
      the treatment of &quot;real world&quot; de-novo and restenotic lesions in native coronary arteries and&#xD;
      coronary bypass grafts. Study goals are based on non-inferiority for Drug-Coated Balloon&#xD;
      (DCB) compared to Paclitaxel-Coated Balloon (PCB) and Dru-eluting Stents (DES) (historical&#xD;
      data) with 80% power. Primary and secondary outcome variables are international accepted&#xD;
      parameters in stent-trials, which sufficiently describe the efficacy and safety of the&#xD;
      investigated device and allow clinical conclusions. Additional attention will be paid to&#xD;
      those patients who received, by observation, a shortened dual antiplatelet therapy (DAPT).&#xD;
&#xD;
      The aim of the study is to assess the safety and efficacy of the SeQuent® SCB in the&#xD;
      treatment of coronary artery disease with reference vessel diameters between ≥ 2 mm and ≤ 4&#xD;
      mm with suitable lesion lengths. There is no limitation of lesion lengths. In case the lesion&#xD;
      is longer than 34 mm, more than one stent needs to be used.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>at 12 months</time_frame>
    <description>Target Lesion Failure (TLF): defined as the composite rate of target vessel myocardial infarction (TV-MI) or ischemia-driven target lesion revascularization (TLR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>at 24 months</time_frame>
    <description>Target Lesion Failure (TLF): defined as the composite rate of target vessel myocardial infarction (TV-MI) or ischemia-driven target lesion revascularization (TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ischemia driven target lesion revascularization (TLR)</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ischemia driven target lesion revascularization (TLR)</measure>
    <time_frame>at 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause death, cardiac death</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause death, cardiac death</measure>
    <time_frame>at 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all myocardial infarction (MI) and target vessel myocardial infarction (TV-MI)</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all myocardial infarction (MI) and target vessel myocardial infarction (TV-MI)</measure>
    <time_frame>at 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major adverse coronary event (MACE)</measure>
    <time_frame>at 12 months</time_frame>
    <description>major adverse coronary event (MACE): defined as composite of cardiovascular death, myocardial infarction or ischemia-driven target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major adverse coronary event (MACE)</measure>
    <time_frame>at 24 months</time_frame>
    <description>major adverse coronary event (MACE): defined as composite of cardiovascular death, myocardial infarction or ischemia-driven target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dual Antiplatelet Therapy (DAPT) compliance</measure>
    <time_frame>at 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dual Antiplatelet Therapy (DAPT) compliance</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probable or definite stent-thrombosis of In-stent treated lesions</measure>
    <time_frame>accumulated at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probable or definite stent-thrombosis of In-stent treated lesions</measure>
    <time_frame>accumulated at 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>immediately after procedure</time_frame>
    <description>final diameter stenosis &lt; 30 % without flow-limiting dissections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications according to the Bleeding Academic Research Consortium (BARC)</measure>
    <time_frame>accumulated at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications according to the Bleeding Academic Research Consortium (BARC)</measure>
    <time_frame>accumulated at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications according to the Bleeding Academic Research Consortium (BARC)</measure>
    <time_frame>accumulated at 24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">1302</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Ischaemia</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SeQuent® SCB drug-coated balloon catheter</intervention_name>
    <description>treatment of coronary artery disease with SeQuent® SCB of &quot;real world&quot; de-novo and restenotic lesions in native coronary arteries and coronary bypass grafts</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This is a single-armed, prospective, international, multi-center, post-market study in&#xD;
        patients with coronary artery disease and indication for PCI either due to anginal symptoms&#xD;
        and a relevant stenotic coronary lesion during angiography or due to documented ischemia by&#xD;
        non-invasive or invasive functional testing.&#xD;
&#xD;
        All patients who undergo a target intervention with the SCB will be followed for 12 and 24&#xD;
        months after initial PCI.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All common significant coronary lesions&#xD;
&#xD;
          -  Target lesion length &gt;34mm need to be covered with at least 2 devices&#xD;
&#xD;
          -  Patients eligible for this study must be at least 18 years of age&#xD;
&#xD;
          -  The patient must fulfil the standard recommendations for percutaneous coronary&#xD;
             intervention (PCI), based on the last ESC recommendations within his/ her regular&#xD;
             treatment or that the use of the product has already been decided within the regular&#xD;
             planning of the patient's treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intolerance to sirolimus&#xD;
&#xD;
          -  Allergy to components of the coating&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Complete occlusion of the treatment vessel because of an unsuccessfully re-canalized&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Risk of an intraluminal thrombus&#xD;
&#xD;
          -  Hemorrhagic diathesis or another disorder such as gastro-intestinal ulceration or&#xD;
             cerebral circulatory disorders which restrict the use of platelet aggregation&#xD;
             inhibitor therapy and anti-coagulation therapy&#xD;
&#xD;
          -  Surgery shortly after myocardial infarction with indications of thrombus or poor&#xD;
             coronary flow behavior&#xD;
&#xD;
          -  Severe allergy to contrast media&#xD;
&#xD;
          -  Lesions which are untreatable with PCI or other interventional techniques&#xD;
&#xD;
          -  Patients with an ejection fraction of &lt; 30 %&#xD;
&#xD;
          -  Vascular reference diameter &lt; 2.00 mm&#xD;
&#xD;
          -  Treatment of the left stem (first section of the left coronary artery)&#xD;
&#xD;
          -  Indication for a bypass surgery&#xD;
&#xD;
          -  Contraindication for whichever accompanying medication is necessary&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvia Otto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Jena - Klinik für Innere Medizin I</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvia Otto, MD</last_name>
    <phone>+49 3641 932 45 60</phone>
    <email>Sylvia.Otto@med.uni-jena.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <state>Thüringen</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Otto, MD</last_name>
      <phone>+49 3641 932 45 60</phone>
      <email>Sylvia.Otto@med.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Sylvia Otto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 10, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2020</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Myocardial Ischemia</keyword>
  <keyword>drug-coated balloon catheter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

